Rules
FDA influencer marketing rules for pharma: what brands must pre-clear
FDA influencer marketing rules for pharma: which sponsored posts need pre-clearance, what a compliant disclosure carries, and who acts when a brand skips the filing.
What to take away
- The FDA treats a paid post about a prescription drug as promotional labeling, so it goes through the same review as a television spot.
- Promotional material goes to the agency on Form FDA 2253 at first dissemination, not after the campaign wraps.
- Two disclosures are needed: the influencer's material connection, which the FTC polices, and risk information in fair balance, which the FDA polices.
- State attorneys general enforce their own consumer protection statutes over the same post.
- A post that runs without review can draw a public warning letter and a misbranding finding under the Food, Drug and Cosmetic Act.
Which regulator sees the post first
FDA's Office of Prescription Drug Promotion, inside the Center for Drug Evaluation and Research, reviews promotion for prescription drugs and biologics. A brand that pays a creator, or writes the script the creator reads, is promoting the drug.
The FTC handles the endorsement side and the health claims themselves. Its influencer guidance says the disclosure has to be clear and conspicuous, and that a platform's paid partnership label does not carry the duty for the advertiser.
| Regulator | What it covers in a sponsored pharma post | Main lever |
|---|---|---|
| FDA, Office of Prescription Drug Promotion | Promotion of prescription drugs and biologics | Filing at first use, fair balance, corrective messaging |
| Federal Trade Commission | Material connection disclosure and health claims | Enforcement action and order terms |
| State attorney general | Consumer protection and advertising law in that state | Investigation, settlement, injunction |
The three regulators run in parallel, not in sequence. A clearance from one does not answer the others.
Clearance also holds only when the contract lets the brand pause a post until review closes. The contracts and disclosure notes cover that clause and the ones next to it.
What a compliant post has to contain
The material connection is the influencer's disclosure to make and the brand's problem if it goes missing. FTC guidance puts it ahead of the caption cut that hides the rest of the text, and inside the video or audio for video posts. A hashtag stack at the end does not qualify.
FDA wants risk information presented with fair balance against the benefit claims. In long formats that is the brief summary, usually called ISI. The established name and the approved indication appear as they do in approved labeling, and a boxed warning is carried word for word. Agency positions sit in guidance documents rather than one rule, searchable in the FDA guidance documents database.
- Signed medical, legal and regulatory review recorded against the post version
- Material connection disclosure inside the first lines of the caption
- Risk information given prominence comparable to the benefit claims
- Boxed warning and established name taken from approved labeling
- Form FDA 2253 filed at the time of first dissemination
A platform label can be accurate and still leave the advertiser short, because the audience is owed a disclosure from the brand that paid.
Example: a sixty-second video that fails review
A brand pays a creator with a chronic illness audience to discuss a new prescription treatment. Legal approves the script. The creator films a second version, adds a claim about faster relief, keeps the paid partnership tag, and moves the risk information into a pinned comment.
Three failures land together. The added claim was never reviewed, the material connection leans on a platform tool alone, and the risk information sits outside the post itself.
A locked campaign briefs strategy stops that second version from existing. The brief holds the approved claims, the required disclosures and the sign-off path in one document.
When a post runs without review
FDA warning letters and untitled letters are public documents. A warning letter conventionally asks for a written response within about 15 working days, along with a plan to correct the promotion.
The larger exposure is statutory. A drug whose labeling is false or misleading in a material way is misbranded, and shipping a misbranded drug is a prohibited act under the Food, Drug and Cosmetic Act.
Who pays for a reshoot is a contract term rather than an afterthought, and the rates and negotiation checklist works through that clause and the ones around it.
Where the rules differ by place
State attorneys general act under their own consumer protection and advertising statutes. A post can clear federal review and still draw a state inquiry. Some states add reporting duties when a paid creator also prescribes the drug being promoted.
The review log is the first thing an investigator asks for. The content approvals notes explain how to keep one that holds together.
Common questions
Does every paid post about a prescription drug need FDA review before it runs? If the brand paid for it or shaped the content, treat it as promotional labeling and send it through the same review as any other ad.
Is a platform's paid partnership label enough disclosure? No. The FTC treats platform tools as a help, not a replacement for the advertiser's own clear disclosure.
What happens when a post goes live unreviewed? The brand files late, pulls the post, and may receive a warning letter. Misbranding exposure does not end when the post comes down.
Do US rules reach a creator filming abroad? US rules attach to promotion of the drug in US channels. The creator's own country may add separate disclosure and tax duties.
